CClinicalTrials.gg
Not yet recruitingNCT03454646Updated Oct 6, 2023

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

A Phase 4 interventional study of cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) in Alzheimer Disease and Cholinesterase Inhibitors, sponsored by University Hospital, Bordeaux. Not yet recruiting at 31 sites in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by University Hospital, Bordeaux · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
1,205
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as "symptomatic treatment" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable.

The investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.

02

Conditions studied

  • Alzheimer Disease
  • Cholinesterase Inhibitors

Browse trials for

03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • New case of AD referring to a CMRR or MC.
  • Diagnosis of probable or possible AD, defined according to the NINCDS-ARDRA criteria
  • Mild to moderate stage, defined by a MMSE score above 15 at the time of pre-inclusion
  • Patients with indication to CI treatment
  • Patients Naïve to CI treatment
  • Patients aged 50 years or more
  • Menopause or effective contraception (for women)
  • Affiliated person or beneficiary of a social security scheme
  • Patients with AD LTI (Long Term Illeness)
  • Patients agree to participate, with free, informed and written consent signed by the patient and his caregiver

Non Inclusion Criteria:

  • Patients diagnosed with Lewy bodies disease, fronto-temporal dementia, or dementia from a cause other than Alzheimer Disease
  • More severe stage of the disease, defined by a MMSE equal or below 15 at the time of inclusion
  • Patients with contraindication to CI treatment
  • Patients residing in an institution at the time of pré-inclusion or randomization
  • Patients with a complete dependency for bathing and dressing at the time of pré-inclusion or randomization ( ADL de Katz, score 2/2 for the item "bathing" and/or "dressing")
  • Patients under tutorship or curatorship, patients unable to express consent
  • Patients with unstable severe general disease compromising the follow-up
  • Patients without caregiver
  • Patients included in another pharmacological trial
  • Pregnant or breastfeeding women

Exclusion criteria

Exclusion Criteria:

  • CI responder patients for whom the MMSE score remained stable or became higher after 6 months of treatment
  • Patients with complete dependency for bathing and dressing at the randomization visit
  • Patients residing in an institution at the randomization visit
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,205 participants (estimated)

Study arms

  • Experimental
    Group randomized for continuing treatment

    Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.

    Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)

  • No intervention
    Group randomized for stopping treatment

    Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.

Interventions

  • Drugcholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)

    The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as "non-responders" or responders. Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.

05

What researchers measure

Primary outcomes

  1. The primary outcome is a combination of complete BADL dependency in bathing and dressing and/or institutionalization or death at 2 years after randomization.

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at 30 months after patient's inclusion

Secondary outcomes

  1. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].

    Each of the components of the combined primary outcome, as defined above, analyzed separately. As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability \[17\] \[18\]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

    Time frame: at inclusion

  2. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].

    Each of the components of the combined primary outcome, as defined above, analyzed separately. As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability \[17\] \[18\]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

    Time frame: at 6 months

  3. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].

    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability \[17\] \[18\]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

    Time frame: at 12 months

  4. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].

    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability \[17\] \[18\]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

    Time frame: at 18 months

  5. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].

    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability \[17\] \[18\]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

    Time frame: at 24 months

  6. BADL dependency will be evaluated by the clinician using the BADL scale from Katz [17].

    Each of the components of the combined primary outcome, as defined above, analyzed separately As previously demonstrated, bathing and dressing are the first ADL losses, also defined by Katz et al. as the thresholds of disability \[17\] \[18\]. A total limitation in bathing and dressing will be considered (each item is coded from 0 - no limitation, to 2 - total limitation).

    Time frame: at 30 months

  7. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at inclusion

  8. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at 6 months

  9. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at 12 months

  10. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at 18 months

  11. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at 24 months

  12. Combination of complete BADL dependency in bathing and dressing and/or institutionalization or death

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information. Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status. For dependency in bathing and dressing, although it could be considered as less objective, we choose a level of total dependency, easy to assess with very low risk of misinterpretation.

    Time frame: at 30 months

  13. Institutionalization with date of entry

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Time frame: at inclusion

  14. Institutionalization with date of entry

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Time frame: at 6 months

  15. Institutionalization with date of entry

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Time frame: at 12 months

  16. Institutionalization with date of entry

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Time frame: at 18 months

  17. Institutionalization with date of entry

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Time frame: at 24 months

  18. Institutionalization with date of entry

    Institutionalization with date of entry will be assessed by specialist at each follow-up time every 6 months. For patients not coming to the memory consultation, caregiver (formal and/or informal) and/or the general practitioner will be systematically contacted to obtain the information.

    Time frame: at 30 months

  19. Death and date of death

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    Time frame: at inclusion

  20. Death and date of death

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    Time frame: at 6 months

  21. Death and date of death

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    Time frame: at 12 months

  22. Death and date of death

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    Time frame: at 18 months

  23. Death and date of death

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    Time frame: at 24 months

  24. Death and date of death

    Death and date of death will be assessed by contacting proxy or general practitioner. In case of lack of information the birth City Hall will be contacted to assess the vital status.

    Time frame: at 30 months

  25. the ADL scale

    ADL DE KATZ BATHING :└-┘/2 0 bathes self completely 1. needs help in bathing only one part of the body 2. needs help with bathing more than one part of the body or not bathed DRESSING :└-┘ /2 0 gets clothes and gets completely dressed without assistance 1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└-┘/2 0 toileting without assistance (may use cane, walker, or wheelchair) 1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└-┘/2 0 transfer without assistance (may be using cane or walker) 1. transfer with assistance 2. doesn't get out of bed. FEEDING :└-┘/2 0 feeding without help 1. need help cutting meat or buttering bread 2. needs total help or requires parenteral feeding. TOTAL : └-┴-┘/10 If the patient has a result of 2 at bathing and or dressing he can't be included at T0.

    Time frame: at inclusion

  26. the ADL scale

    ADL DE KATZ BATHING :└-┘/2 0 bathes self completely 1. needs help in bathing only one part of the body 2. needs help with bathing more than one part of the body or not bathed DRESSING :└-┘ /2 0 gets clothes and gets completely dressed without assistance 1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└-┘/2 0 toileting without assistance (may use cane, walker, or wheelchair) 1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└-┘/2 0 transfer without assistance (may be using cane or walker) 1. transfer with assistance 2. doesn't get out of bed. FEEDING :└-┘/2 0 feeding without help 1. need help cutting meat or buttering bread 2. needs total help or requires parenteral feeding. TOTAL : └-┴-┘/10 If the patient has a result of 2 at bathing and or dressing he can't be randomized at T6M

    Time frame: at 6 months

  27. the ADL scale

    ADL DE KATZ BATHING :└-┘/2 0 bathes self completely 1. needs help in bathing only one part of the body 2. needs help with bathing more than one part of the body or not bathed DRESSING :└-┘ /2 0 gets clothes and gets completely dressed without assistance 1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└-┘/2 0 toileting without assistance (may use cane, walker, or wheelchair) 1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└-┘/2 0 transfer without assistance (may be using cane or walker) 1. transfer with assistance 2. doesn't get out of bed. FEEDING :└-┘/2 0 feeding without help 1. need help cutting meat or buttering bread 2. needs total help or requires parenteral feeding. TOTAL : └-┴-┘/10

    Time frame: at 12 months

  28. the ADL scale

    ADL DE KATZ BATHING :└-┘/2 0 bathes self completely 1. needs help in bathing only one part of the body 2. needs help with bathing more than one part of the body or not bathed DRESSING :└-┘ /2 0 gets clothes and gets completely dressed without assistance 1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└-┘/2 0 toileting without assistance (may use cane, walker, or wheelchair) 1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└-┘/2 0 transfer without assistance (may be using cane or walker) 1. transfer with assistance 2. doesn't get out of bed. FEEDING :└-┘/2 0 feeding without help 1. need help cutting meat or buttering bread 2. needs total help or requires parenteral feeding. TOTAL : └-┴-┘/10

    Time frame: at 18 months

  29. the ADL scale

    ADL DE KATZ BATHING :└-┘/2 0 bathes self completely 1. needs help in bathing only one part of the body 2. needs help with bathing more than one part of the body or not bathed DRESSING :└-┘ /2 0 gets clothes and gets completely dressed without assistance 1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└-┘/2 0 toileting without assistance (may use cane, walker, or wheelchair) 1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└-┘/2 0 transfer without assistance (may be using cane or walker) 1. transfer with assistance 2. doesn't get out of bed. FEEDING :└-┘/2 0 feeding without help 1. need help cutting meat or buttering bread 2. needs total help or requires parenteral feeding. TOTAL : └-┴-┘/10

    Time frame: at 24 months

  30. the ADL scale

    ADL DE KATZ BATHING :└-┘/2 0 bathes self completely 1. needs help in bathing only one part of the body 2. needs help with bathing more than one part of the body or not bathed DRESSING :└-┘ /2 0 gets clothes and gets completely dressed without assistance 1 gets clothes and gets dressed without assistance, except for assistance in tying shoes 2 receives assistance in getting clothes or in getting dressed, or stays partly or completely undressed TOILETING :└-┘/2 0 toileting without assistance (may use cane, walker, or wheelchair) 1 receives assistance 2 doesn't go to room termed " toilet ". TRANSFER:└-┘/2 0 transfer without assistance (may be using cane or walker) 1. transfer with assistance 2. doesn't get out of bed. FEEDING :└-┘/2 0 feeding without help 1. need help cutting meat or buttering bread 2. needs total help or requires parenteral feeding. TOTAL : └-┴-┘/10

    Time frame: at 30 months

  31. the MMSE score

    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

    Time frame: at inclusion

  32. the MMSE score

    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

    Time frame: at 6 months

  33. the MMSE score

    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

    Time frame: at 12 months

  34. the MMSE score

    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

    Time frame: at 18 months

  35. the MMSE score

    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

    Time frame: at 24 months

  36. the MMSE score

    The MMSE score will be assessed by the clinician, the psychologist or the speech therapist according to the habits of the center, using the French version of the MMSE (GRECO version)

    Time frame: at 30 months

  37. the number of hospitalizations

    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

    Time frame: at inclusion

  38. the number of hospitalizations

    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

    Time frame: at 6 months

  39. the number of hospitalizations

    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

    Time frame: at 12 months

  40. the number of hospitalizations

    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

    Time frame: at 18 months

  41. the number of hospitalizations

    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

    Time frame: at 24 months

  42. the number of hospitalizations

    The number of hospitalizations will be assessed using standardized questionnaire, with date (month/year) and duration of hospitalization;

    Time frame: at 30 months

  43. Pharmacologie treatments consumed by the patient

    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

    Time frame: at inclusion

  44. Pharmacologie treatments consumed by the patient

    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

    Time frame: at 6 months

  45. Pharmacologie treatments consumed by the patient

    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

    Time frame: at 12 months

  46. Pharmacologie treatments consumed by the patient

    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

    Time frame: at 18 months

  47. Pharmacologie treatments consumed by the patient

    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

    Time frame: at 24 months

  48. Pharmacologie treatments consumed by the patient

    All the pharmacologie treatments consumed by the patient will be assessed, allowing to assess psychotropic drug consumption.

    Time frame: at 30 months

06

Study locations

31 sites
  • CHU d'Amiens Centre Mémoire Ressources Recherche
    Amiens, 80054, France
  • CHU d'Angers Centre Mémoire Ressources Recherche
    Angers, 49933, France
  • CHU de Bastia Centre Mémoire Ressources Recherche
    Bastia, 20604, France
  • CHU de Besançon Centre Mémoire Ressources Recherche
    Besançon, 25030, France
  • CHU de Bordeaux - Service de Neurologie - Centre Mémoire Ressources Recherche -
    Bordeaux, 33076, France
  • CHRU Cavale Blanche Service de Gériatrie
    Brest, 29200, France
  • Service de Neuropsychologie Hôpital Neurologique Pierre Wertheimer
    Bron, 69677, France
  • CHU Côte de Nacre Service de neurologie et CMRR
    Caen, 14033, France
  • CHU de Clermont Ferrand Centre Mémoire Ressources Recherche
    Clermont-Ferrand, 63000, France
  • Hôpital Pasteur Service de Neurologie
    Colmar, 68000, France
  • CHU de Dijon- CMRR
    Dijon, 21679, France
  • Chu de Grenoble CMRR, Neurologie
    Grenoble, 38043, France
  • Hôpital Roger Salengro CMRR
    Lille, 59037, France
  • CHU Limoges Service de neurologie et CMRR
    Limoges, 87000, France
  • AP-HM
    Marseille, France
  • CHU Montpellier Hôpital Gui de Chauliac CMRR
    Montpellier, 34295, France
  • CHU de Nantes Clinique Neurologique Hôpital GR Laennec
    Nantes, 44093, France
  • Institut Claude Pompidou Centre Mémoire de Ressources et de Recherche
    Nice, 06100, France
  • APHP Hôpital Broca
    Paris, 75013, France
  • Hôpital Universitaire de la Pitié Salpêtrière Pavillon François Lhermitte
    Paris, 75013, France
  • APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal CMRR
    Paris, 75475, France
  • CHU La Milétrie Pôle de Gériatrie
    Poitiers, 86021, France
  • CHU Reims Hôpital Maison Blanche Court Séjour Gériatrique
    Reims, 51092, France
  • CHU de Rennes - Hôpital Pontchaillou / Service de Neurologie
    Rennes, 35033, France
  • CHU de Rouen Hôpital Charles Nicolle Service Neurologie
    Rouen, 76031, France
  • Chu de Saint-Etienne, CMRR
    Saint-Étienne, 42055, France
  • Chu de Strasbourg Hôpital Ka Robertsau Pôle de Gériatrie - CMRR
    Strasbourg, 67200, France
  • Centre de Recherche Clinique du Gérontopôle Cité de la Santé
    Toulouse, France
  • CHRU de Bretonneau Unité de gérontopsychiatrie
    Tours, 37000, France
  • CHU Nancy Service de Gériatrie-CMRR
    Vandoeuvre les nancy, 54511, France
  • Hospice Civil de Lyon Hôpital des Charpennes
    Villeurbanne, 69100, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03454646
Lead sponsor
University Hospital, Bordeaux
Responsible party
Sponsor
First posted
Mar 6, 2018
Start date
Jun 1, 2024 (estimated)
Primary completion
Apr 27, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Oct 6, 2023

Study contacts

Jean-François DARTIGUES, M.D., Ph.D
Contact
jean-francois.dartigues@u-bordeaux.fr
05 57 82 01 16
François TISON, M.D., Ph.D
Contact
francois.tison@chu-bordeaux.fr
05 57 82 12 54

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion